Rezvilutamide Clinical Trials
7 recruitingDrug
Phase 26Phase 31Phase 11
Showing 1–7 of 7 trials
Recruiting
Phase 1Phase 2
A Clinical Study of SHR-4394 in Combination With Anti-tumor Therapy in Prostate Cancer
Prostate Cancer
Jiangsu HengRui Medicine Co., Ltd.100 enrolled2 locationsNCT07407283
Recruiting
Phase 2
Adjuvant Rezvilutamide in Combination With Androgen Deprivation Therapy in Androgen Receptor-positive, High-risk Salivary Duct Carcinoma
Salivary Gland Neoplasm Duct
Peking University First Hospital37 enrolled2 locationsNCT06348264
Recruiting
Phase 2
Genomic Biomarker-guided Neoadjuvant Therapy for Prostate Cancer (SEGNO)
Locally Advanced Prostate CancerOligometastatic Prostate Cancer
The First Affiliated Hospital of Xiamen University40 enrolled1 locationNCT06387056
Recruiting
Phase 2
Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer
Prostate CancerBiochemical Recurrence
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School102 enrolled2 locationsNCT06305832
Recruiting
Phase 3
Comparing the Efficacy and Safety of Rezvilutamide+ADT+Docetaxel Versus Rezvilutamide +ADT in the mHSPC
Chemotherapy EffectMetastatic Prostate CancerHormone Sensitive Prostate Cancer
The First Affiliated Hospital with Nanjing Medical University200 enrolled1 locationNCT05983783
Recruiting
Phase 2
Rezvilutamide in Patients With Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer
Prostate CancerBiochemical Recurrence
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School96 enrolled2 locationsNCT05753566
Recruiting
Phase 2
Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer
Neoadjuvant Therapy
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School900 enrolled1 locationNCT05406999